Fungal infections range from superficial mycoses involving skin or mucous membranes to severe opportunistic infections that may be fatal. The selection of chemotherapeutic agents useful for the treatment of fungal infections includes many topical or systemic imidazoles and triazoles. This overview compares and contrasts the pharmacology and therapeutic use of these agents. This review will focus primarily on these agents' mechanism of action, pharmacokinetics, clinical studies, and adverse reactions.
Get full access to this article
View all access options for this article.
References
1.
KobayashiGMedoffG. The fungi and the mycoses. In: SchaechterMMedoffGSchlessingerD, eds. Mechanisms of microbial disease. Baltimore: Williams & Wilkins, 1989: 495–523.
2.
BorgersM. Mechanism of action of antifungal drugs, with special reference to the imidazole derivative. Rev Infect Dis1980; 2: 520–34.
3.
SudUFeingoldDS. Heterogeneity of action mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother1981; 20: 71–4.
4.
SudIJFeingoldDS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol1981; 76: 438–41.
5.
SaagMSDismukesWE. Azole antifungal agents: Emphasis on new triazoles. Antimicrob Agents Chemother1988; 32: 1–8.
DaneshmendTKWarnockDW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet1988; 14: 13–34.
8.
BebfieldPClissoldSP. Sulconazole: A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs1988; 35: 143–53.
9.
ClissoldSPHeelRC. Tioconazole: A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs1986; 31: 29–51.
10.
HanstenPDHornJR. Drug interactions. Philadelphia: Lea & Febiger, 1989.
11.
LelawongsPBaroneJAColaizziJL. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm1988; 7: 228–35.
12.
WhiteDJGBlatchfordNRCauwenberghG. Cyclosporine and ketoconazole. Transplantation1984; 37: 214–5.
13.
GlynnAMSlaughterRLBrassC. D'AMBROSIO R, JUSKO WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther1986; 39: 654–9.
14.
ZurcherRMFreyBMFreyFJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther1989; 45: 366–72.
15.
BrassCGalgianiJNBlaschkeTFDefeliceRO'ReillyRAStevensDA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother1982; 21: 151–8.
16.
DobleNHykinPShawRKealEE. Pulmonary mycobacterium tuberculosis in acquired immune deficiency syndrome. Br Med J1985; 291: 849.
17.
SudUFeingoldDS. Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrob Agents Chemother1983; 23: 185–7.
18.
IwenPCMillerNGMcFaddenHWJr. Treatment of murine pulmonary cryptococcoses with ketoconazole and amphotericin B. J Infect Dis1984; 149: 650.
19.
RolanPESomogyiAADrewMJRCobainWGSouthDBochnerF. Phenytoin intoxication during treatment with parenteral miconazole. Br Med J1983; 287: 1760.
20.
StevensDA. Miconazole in the treatment of systemic fungal infections (editorial). Am Rev Respir Dis1977; 116: 801–6.
21.
Ketoconazole labeling revised. FDA Drug Bull1984; 14: 17.
22.
LoupiEDescotesJLeryNEvreuxJU. Interactions médicamenteuses et miconazole: A propos de 10 observations. Therapie1982; 37: 437–41.
SmithAG. Potentiation of oral anticoagulants by ketoconazole. Br Med J1984; 288: 188–9.
25.
DrouhetEDupontB. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med1983; 74 (1B): 30–47.
26.
DorseyJKHardyBGWalkerSE. An evaluation of the dose-dependent pharmacokinetics of ketoconazole (abstract). Clin Pharmacol Ther1988; 188: III B.
27.
BrinckerH. Prevention of mycosis in granulocytopenic leukemia patients with prophylactic ketoconazole treatment (abstract). Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1981: 206.
28.
DewitSWeertsDGoossensHClumeckN. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet1989; 1: 746–8.
29.
GrantSMClissoldSP. Itraconazole: A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic use in superficial and systemic mycoses. Drugs1989; 37: 310–44.
30.
TerrellCLHermansPE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc1987; 62: 1116–28.
31.
HeelRCBrogdenRNCarmineAMorleyPASpeightTMAveryGS. Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs1982; 23: 1–36.
32.
GraybilJPalouEAhrensJ. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis1986; 134: 768–70.
33.
SternJJHartmanBJSharkeyP, Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcoses: Experience with 22 patients. Am J Med1988; 85: 477–80.
34.
SugarASaundersC. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med1988; 85: 481–9.
35.
RubinRHDebruinMFKnirschAK. Fluconazole therapy for patients with serious Candida infections who have failed standard therapies (abstract). Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 112.
36.
LarsenRALealME. Fluconazole compared to amphotericin B as treatment of cryptococcal meningitis (abstract). Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 282.
37.
DismukesWCloudGThompsonSSugarATuazonC. Fluconazole (FLU) versus amphotericin B (AMB) therapy (Rx) of acute cryptococcal meningitis (C.M.) (abstract). Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 282.
38.
HansenRMReinerioNSohnlePG, Ketoconazole in the prevention of candidiasis in patients with cancer: A prospective, randomized, controlled, double-blind study. Arch Intern Med1987; 147: 710–2.
WingardJRVaughanWPBraineHGMerzWGSaralR. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med1987; 83: 1103–10.
41.
BrinckerH. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med Scand1978; 204: 123–8.
42.
FeczkdJMBrammerKWBuellDN. Superiority of oral fluconazole (FLU) over oral non-absorbable polyenes (POL) as fungal prophylaxis in neutropenic patients (abstract). Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 112.
43.
TricotGJoostenEBoogaetsMAVande-PitteJCauwenberghG. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies. Rev Infect Dis1987; 9 (suppl 1): 94–9.
44.
LewisJHZimmermanHJBensonGDIshakKG. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases. Gastroenterology1984; 86: 503–13.
National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective randomized clinical trial. Ann Intern Med1985; 103: 861–72.
47.
DefeliceRJohnsonDGGalgianiJN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother1981; 19: 1073–4.
